SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Anavex Molecules Similar, But Each Must Be Tested

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
falconer66a Member Profile
 
Followed By 56
Posts 723
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Annual Report (10-k) "Edgar (US Regulatory)" - 12/11/2017 5:17:35 PM
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs "GlobeNewswire Inc." - 12/11/2017 7:00:00 AM
Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of... "GlobeNewswire Inc." - 11/21/2017 7:00:00 AM
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington... "GlobeNewswire Inc." - 11/8/2017 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clini... "GlobeNewswire Inc." - 11/4/2017 3:30:00 PM
Greenbank Cap, Inc. (OTC Pink: GRNBF) Closes Private Placement as Shares Climb "InvestorsHub NewsWire" - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conferen... "GlobeNewswire Inc." - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 "GlobeNewswire Inc." - 10/27/2017 8:52:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/26/2017 2:50:54 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/24/2017 12:06:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/19/2017 6:47:52 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/18/2017 9:47:41 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2017 11:07:52 AM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Pat... "GlobeNewswire Inc." - 10/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/6/2017 5:18:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/5/2017 5:57:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 7:53:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/29/2017 2:33:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2017 3:10:51 PM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference "GlobeNewswire Inc." - 9/21/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/20/2017 4:51:51 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/19/2017 1:59:44 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/14/2017 2:28:25 PM
Alzheimer’s Disease: Cannabis Formulation Shows Promise "NetworkNewsWire" - 9/12/2017 8:45:00 AM
falconer66a   Saturday, 08/12/17 05:29:20 PM
Re: powerwalker post# 115246
Post # of 133897 
Anavex Molecules Similar, But Each Must Be Tested

Yes, the Anavex sigma-1 receptor agonist molecules, at least the major ones being used in new human trials (only Anavex 2-73 right now), and later. Anavex 3-71, are apparently very similar.

Regardless, if they are different only by a single hydroxide transposed to a new position (among the many dozens of them) FDA would require separate, individual testing for each form of molecule being proposed for approval.

Most likely, such minor changes would not materially change or affect clinical outcomes. Still, FDA has an obligation to make certain that new, minor re-configurations of the molecule are equally safe and efficacious.

Read typical drug molecule patent application text. First will be the lengthy, detailed chemical description of the molecule, in several forms. Most detailed are the chemical names, and then a graphic representation (molecular or structural model).

The proper, complete chemical name of Anavex 2-73 is tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride.

(Would be fun to say that at a cocktail party, when telling the profound future of Anavex. But, no, I don’t do that. I haven’t memorized it. No good purpose. I’ve memorized the Latin names of several hundred plants and animals I work with professionally. My favorite is Silphium terebinthinaceum. Look it up. Great plant.)

Anavex 3-71 is an enantiomer (specific configuration) of this molecule: (2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1Hindol-3-yl)propan-1-one .

Patent drug applications also commonly have text seeking patent protection not only for the specific molecule described and named in the application, but also for any similar molecule that has been chemically modified in minor ways, such as simply moving a hydroxyl (-OH) to another position.

About Anavex for Autism.

Don’t know about this just yet. Because many of the causes of autism occur during cerebral development, at least partially in utero, I’m not certain the Anavex sigma-1 receptor agonists could prevent the neurological mis-connections or malfunctions of the condition. Diagnosis and treatment in utero might be problematic.

But don’t take this conjecture as a “no.” There are a good number of molecules in the Anavex pipeline, with perhaps more to come. I doubt that all have been sufficiently tested in murine models for all of the human diseases that might be treated.

Anavex Life Sciences Corp may eventually have a giant stable of drugs innovatively treating a plethora of diseases and conditions not yet discussed concerning the company. Moreover, as I’ve contended previously, the company many be a great success not only for treatments, but for disease and condition prophylaxis, prevention.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist